Figure 2.
RUNX1 mutations in pDC-AML. (A) Oncoplot of mutations in pDC-AML. (B) Lollipop graph of RUNX1 mutations in pDC-AML. (C) VAF of the major mutations compared with blast percentages. AML, NOS, AML not otherwise specified; AML-MRC, AML with myelodysplasia-related changes; t-AML: therapy-related AML.

RUNX1 mutations in pDC-AML. (A) Oncoplot of mutations in pDC-AML. (B) Lollipop graph of RUNX1 mutations in pDC-AML. (C) VAF of the major mutations compared with blast percentages. AML, NOS, AML not otherwise specified; AML-MRC, AML with myelodysplasia-related changes; t-AML: therapy-related AML.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal